ESR1 and breast carcinoma: A recent comparison of high-dose fulvestrant (an ER downregulator) to the AI anastrozole as first-line treatment for advanced breast cancer revealed that fulvestrant provided a longer time-to-progression (Robertson et al., 2009a).